← Back to Screener
Indaptus Therapeutics, Inc. Common Stock (INDP)
Price$3.04
Favorite Metrics
Price vs S&P 500 (26W)-42.11%
Price vs S&P 500 (4W)39.10%
Market Capitalization$6.08M
All Metrics
Book Value / Share (Quarterly)$1.45
P/TBV (Annual)0.70x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-6.84
Price vs S&P 500 (YTD)-9.52%
EPS (TTM)$-25.59
10-Day Avg Trading Volume0.11M
EPS Excl Extra (TTM)$-25.59
EPS (Annual)$-21.58
ROI (Annual)-661.54%
Cash / Share (Quarterly)$3.93
ROA (Last FY)-223.94%
EBITD / Share (TTM)$-20.34
ROE (5Y Avg)-249.93%
Cash Flow / Share (Annual)$-6.84
P/B Ratio1.93x
P/B Ratio (Quarterly)1.62x
Net Income / Employee (Annual)$-3
Net Interest Coverage (TTM)-17.08x
ROA (TTM)-293.64%
EPS Incl Extra (Annual)$-21.58
Current Ratio (Annual)1.51x
Quick Ratio (Quarterly)1.38x
3-Month Avg Trading Volume0.50M
52-Week Price Return-81.02%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.83
52-Week High$19.91
EPS Excl Extra (Annual)$-21.58
Tangible BV CAGR (5Y)-15.97%
26-Week Price Return-38.13%
Quick Ratio (Annual)1.38x
13-Week Price Return-13.97%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)1.51x
Enterprise Value$-2.431
Book Value / Share Growth (5Y)-35.92%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$3.93
3-Month Return Std Dev112.88%
Net Income / Employee (TTM)$-3
ROE (Last FY)-661.54%
Net Interest Coverage (Annual)-6.11x
EPS Basic Excl Extra (Annual)$-21.58
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-25.59
Receivables Turnover (Annual)0.00x
ROI (TTM)-443.87%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.93
Price vs S&P 500 (52W)-110.85%
Year-to-Date Return-6.87%
5-Day Price Return46.49%
EPS Normalized (Annual)$-21.58
ROA (5Y Avg)-120.40%
Month-to-Date Return48.90%
Cash Flow / Share (TTM)$-1.80
EBITD / Share (Annual)$-20.39
ROI (5Y Avg)-249.93%
EPS Basic Excl Extra (TTM)$-25.59
P/TBV (Quarterly)1.13x
P/B Ratio (Annual)1.62x
Book Value / Share (Annual)$1.45
Price vs S&P 500 (13W)-14.66%
Beta1.26x
Revenue / Share (TTM)$0.00
ROE (TTM)-443.87%
52-Week Low$1.51
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
INDPIndaptus Therapeutics, Inc. Common Stock | — | — | — | — | $3.04 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Indaptus Therapeutics is a pre-clinical biotechnology company developing a proprietary bacterial-based immunotherapy platform targeting cancer and viral infections. Its lead candidate, Decoy20, has demonstrated anti-tumor activity in preclinical models as both a single agent and in combination therapy across multiple cancer types, including colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma.